Discussion
nausea, flatulence, diarrhea, ’, headache, T2DM
There is little elucidation regarding treatment-related QoL, specifically in the Pakistani population. Thus, Sitagliptin treatment for glycemic control also improves patient satisfaction, leading to improved QoL, a reasonable hypothesis that is the primary endpoint assessed in the present study. It was observed that after 24 weeks of Sitagliptin medication, the QoL scores improved (p < 0.01). The scores of satisfaction, impact, and worry considerably changed during and after the treatment. Consistent with our findings, Sakamoto et al. demonstrated higher treatment-related QoL beyond glycemic control [In this study, it was found that Sitagliptin can reduce levels of HbA1c and FPG. After 12 weeks, there was a reduction of 0.94% and 39.76 mg/dl, respectively. And after 24 weeks, it was 1.24% and 46.63 mg/dl, respectively (Table The present study observed that abdominal discomfort, nausea, flatulence, and indigestion were Sitagliptin’s most common AEs. The results of the present study are consistent with previous research conducted by Chawla et al., who reported headache, diarrhea, and nausea as the most common side effects associated with Sitagliptin in a randomized controlled trial [There is a dearth of local literature; hence, this study adds local evidence regarding the necessity of monitoring QoL measures and emphasizes the demand for T2DM patients’ QoL-improving therapies. The study also emphasizes how important it is for medical professionals to consider patient QoL factors while managing T2DM patients. However, as mentioned, one limitation of this study is that it was a single-arm study and did not compare the effectiveness of Sitagliptin plus Metformin treatment against a control group. Therefore, it is difficult to determine whether the observed improvements in QoL and glycemic control were solely due to the treatment or could be attributed to other factors. Nevertheless, the results of this study align with previous literature that emphasizes the importance of monitoring multiple parameters beyond just glycemic control in the management of T2DM. The study also highlights the potential benefits of Sitagliptin in improving patients’ QoL measures and glycemic control. In practice, healthcare providers could consider using Sitagliptin as part of a treatment plan for T2DM patients experiencing a decline in their QoL measures. Additionally, larger studies with a control group could provide more robust evidence of Sitagliptin’s effectiveness in improving QoL measures in T2DM patients.